Wegener Marie, Bader Augustinus, Giri Shibashish
Centre for Biotechnology and Biomedicine, Department of Cell Techniques and Applied Stem Cell Biology, Medical Faculty of University of Leipzig, Deutscher Platz 5, Leipzig D-04103, Germany.
Centre for Biotechnology and Biomedicine, Department of Cell Techniques and Applied Stem Cell Biology, Medical Faculty of University of Leipzig, Deutscher Platz 5, Leipzig D-04103, Germany.
Drug Discov Today. 2015 Jun;20(6):667-85. doi: 10.1016/j.drudis.2015.02.010. Epub 2015 Feb 23.
The recently developed ability to differentiate primary adult stem cells and induced pluripotent stem cells (iPSCs) into cardiomyocytes is providing unprecedented opportunities to produce an unlimited supply of cardiomyocytes for use in patients with heart disease. Here, we examine the evidence for the preclinical use of such cells for successful heart regeneration. We also describe advances in the identification of new cardiac molecular and cellular targets to induce proliferation of cardiomyocytes for heart regeneration. Such new advances are paving the way for a new innovative drug development process for the treatment of heart disease.
最近发展起来的将原代成体干细胞和诱导多能干细胞(iPSC)分化为心肌细胞的能力,为心脏病患者提供了无限量的心肌细胞,带来了前所未有的机遇。在此,我们审视这类细胞用于心脏再生的临床前应用证据。我们还描述了在识别新的心脏分子和细胞靶点以诱导心肌细胞增殖实现心脏再生方面的进展。这些新进展正在为治疗心脏病的新型创新药物研发进程铺平道路。